Cargando…

Formulation and characterization of eprosartan mesylate and β-cyclodextrin inclusion complex prepared by microwave technology

The goal of this work was to improve the aqueous solubility and dissolution rate of eprosartan mesylate by preparing inclusion complex of drug with β-cyclodextrin (β-CD) by microwave technique. In order to determine the solubility of eprosartan, phase solubility was determined and dissolution study...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahad, Abdul, Bin Jardan, Yousef A., Hassan, Mohd. Zaheen, Raish, Mohammad, Ahmad, Ajaz, Al-Mohizea, Abdullah M., Al-Jenoobi, Fahad I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116268/
https://www.ncbi.nlm.nih.gov/pubmed/35549506
http://dx.doi.org/10.1080/10717544.2022.2072540
_version_ 1784710083484057600
author Ahad, Abdul
Bin Jardan, Yousef A.
Hassan, Mohd. Zaheen
Raish, Mohammad
Ahmad, Ajaz
Al-Mohizea, Abdullah M.
Al-Jenoobi, Fahad I.
author_facet Ahad, Abdul
Bin Jardan, Yousef A.
Hassan, Mohd. Zaheen
Raish, Mohammad
Ahmad, Ajaz
Al-Mohizea, Abdullah M.
Al-Jenoobi, Fahad I.
author_sort Ahad, Abdul
collection PubMed
description The goal of this work was to improve the aqueous solubility and dissolution rate of eprosartan mesylate by preparing inclusion complex of drug with β-cyclodextrin (β-CD) by microwave technique. In order to determine the solubility of eprosartan, phase solubility was determined and dissolution study was also conducted. Further, analytical techniques for instance, particle size distribution, differential scanning calorimetry, powder X-ray diffraction, scanning electron microscopy, Fourier-transform infrared spectroscopy, and nuclear magnetic resonance spectroscopy were used for the characterization of inclusion complex. In addition, the binding pattern of eprosartan with the β-CD was investigated by molecular modeling study. Phase solubility study revealed that approximately 4.48 folds improvement in the solubility of drug was noted with β-CD (10 mM). The estimated stability constant (K(c)) values for eprosartan:β-CD binary mixture was found to be 280.78 M(–1). The prepared inclusion complex of drug with β-CD presented better drug release profile (62.96 ± 2.01% in 1 h) as compared to their physical mixture (41.41 ± 1.77% in 1 h) or drug per se (29.97 ± 3.13%). The inclusion complex demonstrated different features and properties from pure drug, and we inferred that this could be due to the inclusion of drug into cyclodextrin cavity that confirmed by different analytical method. Molecular modeling study demonstrated a good affinity of eprosartan to entangle to β-CD. The outcomes have shown that guest molecule has many significant interactions with the host molecule. These observations are very interesting and may be a valuable approach to improve the solubility and in turn the bioavailability of eprosartan.
format Online
Article
Text
id pubmed-9116268
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-91162682022-05-19 Formulation and characterization of eprosartan mesylate and β-cyclodextrin inclusion complex prepared by microwave technology Ahad, Abdul Bin Jardan, Yousef A. Hassan, Mohd. Zaheen Raish, Mohammad Ahmad, Ajaz Al-Mohizea, Abdullah M. Al-Jenoobi, Fahad I. Drug Deliv Research Article The goal of this work was to improve the aqueous solubility and dissolution rate of eprosartan mesylate by preparing inclusion complex of drug with β-cyclodextrin (β-CD) by microwave technique. In order to determine the solubility of eprosartan, phase solubility was determined and dissolution study was also conducted. Further, analytical techniques for instance, particle size distribution, differential scanning calorimetry, powder X-ray diffraction, scanning electron microscopy, Fourier-transform infrared spectroscopy, and nuclear magnetic resonance spectroscopy were used for the characterization of inclusion complex. In addition, the binding pattern of eprosartan with the β-CD was investigated by molecular modeling study. Phase solubility study revealed that approximately 4.48 folds improvement in the solubility of drug was noted with β-CD (10 mM). The estimated stability constant (K(c)) values for eprosartan:β-CD binary mixture was found to be 280.78 M(–1). The prepared inclusion complex of drug with β-CD presented better drug release profile (62.96 ± 2.01% in 1 h) as compared to their physical mixture (41.41 ± 1.77% in 1 h) or drug per se (29.97 ± 3.13%). The inclusion complex demonstrated different features and properties from pure drug, and we inferred that this could be due to the inclusion of drug into cyclodextrin cavity that confirmed by different analytical method. Molecular modeling study demonstrated a good affinity of eprosartan to entangle to β-CD. The outcomes have shown that guest molecule has many significant interactions with the host molecule. These observations are very interesting and may be a valuable approach to improve the solubility and in turn the bioavailability of eprosartan. Taylor & Francis 2022-05-13 /pmc/articles/PMC9116268/ /pubmed/35549506 http://dx.doi.org/10.1080/10717544.2022.2072540 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ahad, Abdul
Bin Jardan, Yousef A.
Hassan, Mohd. Zaheen
Raish, Mohammad
Ahmad, Ajaz
Al-Mohizea, Abdullah M.
Al-Jenoobi, Fahad I.
Formulation and characterization of eprosartan mesylate and β-cyclodextrin inclusion complex prepared by microwave technology
title Formulation and characterization of eprosartan mesylate and β-cyclodextrin inclusion complex prepared by microwave technology
title_full Formulation and characterization of eprosartan mesylate and β-cyclodextrin inclusion complex prepared by microwave technology
title_fullStr Formulation and characterization of eprosartan mesylate and β-cyclodextrin inclusion complex prepared by microwave technology
title_full_unstemmed Formulation and characterization of eprosartan mesylate and β-cyclodextrin inclusion complex prepared by microwave technology
title_short Formulation and characterization of eprosartan mesylate and β-cyclodextrin inclusion complex prepared by microwave technology
title_sort formulation and characterization of eprosartan mesylate and β-cyclodextrin inclusion complex prepared by microwave technology
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116268/
https://www.ncbi.nlm.nih.gov/pubmed/35549506
http://dx.doi.org/10.1080/10717544.2022.2072540
work_keys_str_mv AT ahadabdul formulationandcharacterizationofeprosartanmesylateandbcyclodextrininclusioncomplexpreparedbymicrowavetechnology
AT binjardanyousefa formulationandcharacterizationofeprosartanmesylateandbcyclodextrininclusioncomplexpreparedbymicrowavetechnology
AT hassanmohdzaheen formulationandcharacterizationofeprosartanmesylateandbcyclodextrininclusioncomplexpreparedbymicrowavetechnology
AT raishmohammad formulationandcharacterizationofeprosartanmesylateandbcyclodextrininclusioncomplexpreparedbymicrowavetechnology
AT ahmadajaz formulationandcharacterizationofeprosartanmesylateandbcyclodextrininclusioncomplexpreparedbymicrowavetechnology
AT almohizeaabdullahm formulationandcharacterizationofeprosartanmesylateandbcyclodextrininclusioncomplexpreparedbymicrowavetechnology
AT aljenoobifahadi formulationandcharacterizationofeprosartanmesylateandbcyclodextrininclusioncomplexpreparedbymicrowavetechnology